AbbVie has written the next chapter in its epic quest to treat psychiatric disorders, agreeing to buy a psychedelic drug candidate from Gilgamesh Pharmaceuticals for up to $1.2 billion. Bloomberg ...

Aug 25 - AbbVie (ABBV.N), opens new tab will buy an experimental depression drug from partner Gilgamesh Pharmaceuticals for up to $1.2 billion, the companies said on Monday, seeking to access a ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. AbbVie on Monday said it ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie plans to buy Gilgamesh Pharmaceuticals' lead ...

AbbVie’s (NYSE:ABBV) move to buy New York-based psychedelic drug developer Gilgamesh Pharmaceuticals in a deal worth around $1B, according to Bloomberg News, rallied the psychedelic space on Thursday.

AbbVie Inc.'s Q2 2025 results highlight Skyrizi and Rinvoq's dominance, replacing Humira and driving impressive revenue growth, with both drugs exceeding expectations. The company’s aggressive ...

July 30 (Reuters) - Drugmaker AbbVie (ABBV.N), opens new tab is in talks to acquire privately-held mental health therapeutics company Gilgamesh Pharmaceuticals in a deal worth about $1 billion, ...